These downregulated NF-κB targets also include PD-L1, a key immune checkpoint factor, whose abnormal expression in tumor cells suppresses cancer immunity through the binding of PD-L1 to its homologous receptor PD-1 on T cells, resulting in its inactivation and apoptosis (20, 33). The gene discussed is NFKB1; the disease is neoplasm.